Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome

Journal of Pineal Research

Volumn 54, Issue 3, 2013, Pages 346-358

  Corrales, Andrea ^a   Martínez, Paula ^a   García, Susana ^a   Vidal, Verõnica ^a   García, Eva ^a   Flõrez, Jesús ^a   Sanchez Barcelõ, Emilio J ^a   Martínez Cué, Carmen ^a   Rueda, Noemí ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

amyloid precursor protein; cholinergic degeneration; Down syndrome; learning and memory; melatonin; Ts65Dn

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; INDOLEAMINE; MELATONIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN DEGENERATION; BRAIN TISSUE; CHOLINERGIC NERVE CELL; CHOLINERGIC STIMULATION; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; DRUG EFFECT; EXPLORATORY BEHAVIOR; FEMALE; FOREBRAIN; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; LONG TERM CARE; MALE; MAZE TEST; MEMORY; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; SENSORIMOTOR FUNCTION; SPATIAL LEARNING; TREATMENT DURATION;

ADMINISTRATION, ORAL; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOWN SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIPPOCAMPUS; MALE; MAZE LEARNING; MELATONIN; MICE; NERVE DEGENERATION;

EID: 84874950768     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12037     Document Type: Article

References (75)

1. Lott IT, Head E,. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev 2001; 7: 172-178. (Pubitemid 32843808)
2. Lott IT, Head E, Doran E, et al. Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 2006; 3: 521-528. (Pubitemid 46066428)
3. Teipel SJ, Hampel H,. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet 2006; 36: 405-415. (Pubitemid 43876779)
4. Wisniewski KE, Wisniewski HM, Wen GY,. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985; 17: 278-282. (Pubitemid 15136603)
5. Sturgeon X, Gardiner KJ,. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 2011; 22: 261-271.
6. Das I, Reeves RH,. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 2011; 4: 596-606.
7. Bartesaghi R, Guidi S, Ciani E,. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Rev Neurosci 2011; 22: 419-455.
8. Rueda N, Flõrez J, Martínez-Cué C,. Mouse models of down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast 2012; 2012: 584071.
9. Risser D, Lubec G, Cairns N, et al. Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 1997; 60: 1231-1237. (Pubitemid 27191762)
10. Granholm A-CH, Sanders LA, Crnic LS,. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 2000; 161: 647-663. (Pubitemid 30137022)
11. Hunter CL, Bimonte-Nelson HA, Granholm AC,. Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 2003; 138: 121-131. (Pubitemid 36071351)
12. Baxter MG, Chiba AA,. Cognitive functions of the basal forebrain. Curr Opin Neurobiol 1999; 9: 178-183. (Pubitemid 29201789)
13. Wolvetang EJ, Bradfield OM, Tymms M, et al. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome. Biochim Biophys Acta 2003; 1628: 105-110. (Pubitemid 37288895)
14. Seo H, Isacson O,. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 2005; 193: 469-480. (Pubitemid 40626769)
15. Rueda N, Llorens-Martin M, Florez J, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 2010; 21: 277-290.
16. Hunter CL, Isacson O, Nelson M, et al. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Lett 2003; 45: 437-445. (Pubitemid 36355843)
17. Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-β deposition in down syndrome. J Neuropathol Exp Neurol 2000; 59: 1011-1017.
18. Shichiri M, Yoshida Y, Ishida N, Et AL,. Alpha-Tocopherol suppresses lipid peroxidation and behavioural and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 2011; 15: 801-811.
19. Stéphan A, Laroche S, Davis S,. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci 2001; 21: 5703-5714. (Pubitemid 32692169)
20. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539. (Pubitemid 34288854)
21. Head E, Azizeh BY, Lott IT, et al. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol Dis 2001; 8: 252-265. (Pubitemid 32382479)
22. Netzer WJ, Powell C, Nong Y, et al. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS ONE 2010; 5: e10943.
23. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51: 17-43.
24. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonina pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011; 93: 350-384.
25. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
26. Tan DX, Manchester LC, Terron MP, et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J Pineal Res 2007; 42: 28-42. (Pubitemid 44924323)
27. Tan DX, Hardeland R, Manchester LC, et al. Emergence of naturally occurring melatonin isomers and their proposed nomenclature. J Pineal Res 2012; 53: 113-121.
28. Reiter RJ,. Normal patterns of melatonin levels in the pineal gland and body fluids of humans and experimental animals. J Neural Transm 1986; 21: 35-54.
29. Reiter RJ,. The ageing pineal gland and its physiological consequences. BioEssays 1992; 14: 169-175.
30. Reiter RJ,. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56: 359-384. (Pubitemid 28389724)
31. Feng Z, Chang Y, Cheng Y, et al. Melatonin alleviates behavioural deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer′s disease. J Pineal Res 2004; 37: 129-136. (Pubitemid 39120217)
32. Matsubara E, Bryant-Thomas T, Pacheco-Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer′s disease. J Neurochem 2003; 85: 1101-1108. (Pubitemid 36613258)
33. Olcese JM, Chao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009; 47: 82-96.
34. Dragicevic N, Copes N, O'Neal-Moffitt G, et al. Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 2011; 51: 75-86.
35. Liu DP, Schmidt C, Billings T, et al. Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Biotechniques 2003; 35: 1170-1174.
36. Rueda N, Florez J, Martinez-Cue C,. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome. Behav Brain Res 2008; 188: 355-367.
37. Rueda N, Florez J, Martinez-Cue C,. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 2008; 433: 22-27.
38. Rodgers RJ, Johnson JT,. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus maze of anxiety. Pharmacol Biochem Behav 1995; 52: 297-303.
39. Whishaw IQ,. Formation of a place learning-set by the rat: a new paradigm for neurobehavioral studies. Physiol Behav 1985; 35: 139-143. (Pubitemid 15018743)
40. Frankling KBJ, Paxinos G, (1997). The mouse brain in stereotaxic coordinates. Academic Press, San Diego, CA.
41. Lowry OH, Roseborough NJ, Farr AL, et al. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
42. Jeong JK, Moon MH, Seol JW, et al. Melatonin -induced autophagy protects against human prion protein-mediated neurotoxicity. J Pineal Res 2012; 53: 138-146.
43. Escorihuela RM, Fernández-Teruel A, Vallina IF, et al. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 1995; 199: 143-146.
44. Rasmussen DD, Boldt BM, Wilkinson CW, et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140: 1009-1012. (Pubitemid 29058243)
45. Uberos J, Romero J, Molina-Carballo A, et al. Melatonin and elimination of kynurenines in children with Down's syndrome. J Pediatr Endocrinol Metab 2010; 23: 277-282.
46. Reiter RJ, Barlow-Walden L, Poeggeler B, et al. Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects. J Pineal Res 1996; 20: 45-50.
47. Martinez-Cue C, Rueda N, Garcia E, et al. Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behav Brain Res 2005; 163: 174-185. (Pubitemid 41138051)
48. Yoo DY, Kim W, Lee CH, et al. Melatonin improves D-galactose-induced aging effects on behavior, neurogenesis, and lipid peroxidation in the mouse dentate gyrus via increasing pCREB expression. J Pineal Res 2012; 52: 21-28.
49. Baydas G, Yasar A, Tuzcu M,. Comparison of the impact of melatonin on chronic ethanol-induced learning and memory impairment between young and aged rats. J Pineal Res 2005; 39: 346-352.
50. Tuzcu M, Baydas G,. Effects of melatonin and vitamin E on diabetes-induced learning and memory impairment in rats. Eur J Pharmacol 2006; 537: 106-110.
51. Feng Z, Cheng Y, Zhang JT,. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res 2004; 37: 198-206. (Pubitemid 39274118)
52. Whishaw IQ, Mittleman G,. Visits to starts, routes and places by rats (Rattus norvergicus) in swimming pool navigation tasks. J Comp Psychol 1986; 100: 422-431.
53. Florian C, Roullet P,. Hippocampal CA3-region is crucial for acquisition and memory consolidation in Morris water maze task in mice. Behav Brain Res 2004; 154: 365-374. (Pubitemid 39093987)
54. Millan Sanchez M, Heyn SN, Das D, et al. Neurobiological elements of cognitive dysfunction in Down syndrome: exploring the role of APP. Biol Psychiatry 2012; 71: 403-409.
55. Schliebs R, Arendt T,. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-563.
56. Martínez-Serrano A, Fischer W, Söderström S, et al. Long-term functional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain. Proc Natl Acad Sci USA 1996; 93: 6355-6360. (Pubitemid 26230309)
57. Chang HM, Huang YL, Lan CT, et al. Melatonin preserves superoxide dismutase activity in hypoglossal motoneurons of adult rats following peripheral nerve injury. J Pineal Res 2008; 44: 172-180.
58. Busciglio J, Yankner BA,. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995; 378: 776-779. (Pubitemid 26004408)
59. Lockrow J, Prakasam A, Huang P, et al. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 2009; 216: 278-289.
60. Reiter RJ,. Antioxidant actions of melatonin. Adv Pharmacol 1997; 38: 103-117.
61. Jou MJ, Peng TI, Yu PZ, et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007; 43: 389-403.
62. Barlow-Walden LR, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995; 26: 497-502.
63. Maity P, Bindu S, Dey S, et al. Melatonin reduces indomethacin-induced gastric mucosal cell apoptosis by preventing mitochondrial oxidative stress and the activation of mitochondrial pathway of apoptosis. J Pineal Res 2009; 3: 314-323.
64. Radogna F, Cristofanon S, Paternoster L, et al. Melatonin antagonizes the intrinsic pathway of apoptosis via mitochondrial targeting of Bcl-2. J Pineal Res 2008; 44: 316-325. (Pubitemid 351392945)
65. Rueda N, Flõrez J, Matínez-Cué C,. The Ts65Dn mouse model of Down syndrome shows reduced expression of the Bcl-X(L) antiapoptotic protein in the hippocampus not accompanied by changes in molecular or cellular markers of cell death. Int J Dev Neurosci 2011; 29: 711-716.
66. Rueda N, Flõrez J, Martínez-Cué C,. Apoptosis in Down's syndrome: lessons from studies of human and mouse models. Apoptosis 2012. Doi: 10.1007/s10495-012-0785-3.
67. Isacson O, Seo H, Lin L, Albeck D, et al. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 2002; 25: 79-84. (Pubitemid 34123299)
68. Salehi A, Delcroix JD, Belichenko PV, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006; 51: 29-42. (Pubitemid 43963336)
69. Rosales-Corral SA, Acuña-Catroviejo D, Coto-Montes A, et al. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012; 52: 167-202.
70. Coussons-Read ME, Crnic LS,. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field. Behav Genet 1996; 26: 7-13. (Pubitemid 26073018)
71. Martínez-Cué C, Rueda N, García E, et al. Anxiety and panic responses to a predator in male and female Ts65Dn mice, a model of Down syndrome. Genes Brain Behav 2006; 5: 413-422. (Pubitemid 44000926)
72. King MG, Stinus L, Le Moal M, et al. Central administration of arginine vasotocin: effects on exploratory behavior in the rat. Psychopharmacology 1982; 76: 40-43. (Pubitemid 12187360)
73. Karakaş A, Coşkun H, Kaya A, et al. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav Brain Res 2011; 222: 141-150.
74. Costa ACS, Walsh K, Davisson MT,. Motor dysfunction in a mouse model for Down syndrome. Physiol Behav 1999; 68: 211-220. (Pubitemid 30009803)
75. Holtzman DM, Santucci D, Kilbridge J, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 1996; 93: 13333-13338. (Pubitemid 26382816)